Vbi Vaccines Inc/bc 8-K filings

VBI Vaccines Inc. has completed its acquisition by K2 VBI Equity Trust, LLC, an affiliate of K2 HealthVentures LLC, and has emerged from creditor protection proceedings.

VBI Vaccines has provided an update on its restructuring proceedings, including a partial revocation order from the British Columbia Securities Commission to facilitate a transaction with K2 VBI Equity Trust.

VBI Vaccines Inc. has initiated restructuring proceedings under the Companies' Creditors Arrangement Act in Canada and Chapter 15 of the U.S. Bankruptcy Code, leading to its delisting from Nasdaq.

VBI Vaccines has commenced voluntary restructuring under the Companies' Creditors Arrangement Act (CCAA) in Canada, along with related proceedings in the U.S. and Israel, and secured debtor-in-possession financing.

VBI Vaccines held its 2024 Annual General Meeting, where shareholders elected directors and approved the appointment of EisnerAmper LLP as the company's independent auditor.

VBI Vaccines reports positive interim tumor response data from its Phase 2b study of VBI-1901 in recurrent glioblastoma, showing a 43% disease control rate compared to 0% in the control arm.

VBI Vaccines Inc. has received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement, placing its listing status at risk.

VBI Vaccines reports a 105% year-over-year increase in PreHevbrio global net revenue for the first quarter of 2024, alongside encouraging early data from its VBI-1901 glioblastoma study.

VBI Vaccines has received a second 180-day extension from Nasdaq to meet the minimum bid price requirement for continued listing.

VBI Vaccines announced a 234% increase in PreHevbrio global net revenue year-over-year and encouraging early data from a Phase 2b study of VBI-1901 in recurrent glioblastoma.

VBI Vaccines has successfully completed a $2 million registered direct offering, issuing common shares and warrants to institutional investors.

VBI Vaccines reported early positive tumor response data from its Phase 2b study of VBI-1901 in recurrent glioblastoma, showing a 40% disease control rate in the treatment arm compared to 0% in the control arm.

VBI Vaccines has expanded its collaboration with the Canadian government, securing CAD$28 million in funding to advance its mRNA-launched enveloped virus-like particle (MLE) vaccine technology.

VBI Vaccines has entered into agreements with Brii Biosciences to sell manufacturing capabilities, intellectual property, and grant licenses, aiming to reduce debt and streamline operations.

VBI Vaccines has extended its forbearance agreement with K2 HealthVentures to February 20, 2024, due to a failure to meet minimum net revenue covenants.

VBI Vaccines has extended its forbearance agreement with K2 HealthVentures for a fifth time, now through February 6, 2024, due to a failure to meet minimum net revenue covenants.

VBI Vaccines has extended its forbearance agreement with lenders for a further two weeks, as it continues to address a breach of its minimum net revenue covenant.